chiron is a pre-clinical CRO and platform company specializing in advanced, human-relevant in vitro models for translational drug discovery and development.

We partner with pharma and biotech organizations to generate predictive efficacy, safety, and mechanistic data that supports confident decision-making early in development — before costly in vivo and clinical studies.

Our proprietary platforms integrate 3D biology, mechanobiology, and flexible study design to address disease areas where conventional in vitro models fail to capture key biological drivers.

What makes chiron different
• Human relevance first: disease-relevant architecture, human cells, and physiological cues
• Mechanism matters: beyond phenotypes, we deliver mechanistic insight
• Decision-grade data: designed to inform real go/no-go decisions
• Flexible partnership: bespoke studies aligned with program needs

Core disease areas
• Oncology & Immuno-Oncology
• Arthritis & Joint Disease

Our platforms

µMass™ — A scalable 3D micro-aggregate platform enabling reproducible, long-term efficacy, toxicity, and MOA studies compatible with standard laboratory workflows.

Re-Plate™ — A mechanobiology-enabled in vitro platform that incorporates controlled mechanical stimulation to reveal force-dependent disease mechanisms and drug responses.

Who we work with
• Pharma & biotech teams seeking translational confidence
• Researchers adopting advanced in vitro systems for biologically relevant studies

chiron delivers in vitro data designed not just to inform — but to decide.

chiron

Org chart

Teams

Offices